Skip to main content
Premium Trial:

Request an Annual Quote

Steven Kriegsman and Bruce Spiegelman

Premium

CytRx CEO Steven Kriegsman is scheduled to present at the Roth Capital Partners’ annual growth stock conference on Feb. 19, 2004, the company said this week.

Kriegsman is expected to highlight CytRx’s recent collaborations in the field of RNAi and small-molecule drug development, and also give an overview of the company’s other drug development programs.

The Roth meeting is scheduled for Feb. 16-19 at the St. Regis Monarch Beach Resort and Spa in Dana Point, Calif.

CytRx also announced this week that Bruce Spiegelman has joined the scientific advisory board of the company’s subsidiary Araios.

Spiegelman, said CytRx, is a professor of cell biology at Harvard Medical School’s Dana Farber Cancer Institute. His work focuses on the molecular basis of cell differentiation and tissue development, using adipogenesis as a model system.

Spiegelman holds a BS from the College of William and Mary and a PhD from Princeton University.

Also on Araios’ scientific advis- ory board are Michael Czech, professor and chair of molecular medicine at the University of Massachusetts Medical School, Ronald Kahn, president and director of the Joslin Diabetes Center, and Luciano Rossetti, professor and director of diabetes research at the Albert Einstein College of Medicine.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.